Insilico, newly listed in Hong Kong, strikes up to $888M oncology deal with Servier

Days after going public on the Hong Kong Stock Exchange, Insilico Medicine has struck a multi-year oncology drug discovery partnership with France’s Servier worth up to $888 million. The collaboration will focus on developing oncology therapies, by combining Insilico’s AI-driven drug discovery platforms with Servier’s global expertise in cancer drug development.  Insilico pointed to its… The post Insilico, newly listed in Hong Kong, strikes up to $888M oncology deal with Servier appeared first on Drug Discovery and Development.

Continue reading →